|Bid||121.14 x 800|
|Ask||135.00 x 1000|
|Day's range||124.34 - 126.32|
|52-week range||100.39 - 135.05|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||80.78|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||0.96 (0.79%)|
|Ex-dividend date||29 Sept 2022|
|1y target est||123.91|
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.
Earlier today, ZimVie released financial results for the quarter ended September 30, 2022. Before we begin, I'd like to remind you that management will make comments during the call that include forward-looking statements.
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.